11

12
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, December 8, 1998: US05847007 (12 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


13
David J Grainger, James C Metcalfe, Peter L Weissberg: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth P A, December 26, 2000: US06166090 (2 worldwide citation)

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are charac ...


14
Lawrence L Kunz, Richard A Klein, John M Reno, David J Grainger, James C Metcalfe, Peter L Weissberg, Peter G Anderson: Therapeutic inhibitor of vascular smooth muscle cells. NeoRx Corporation, Schwegman Lundberg Woessner & Kluth, January 31, 2002: US20020013275-A1

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a ce ...


15
Grainger David J, Metcalfe James C, Peter L Weissberg, Kemp Paul R: Prevention and treatment of pathogeny associated with abnormally proliferative smooth muscle cell. Poniard Pharmaceuticals, April 5, 2007: JP2007-084570

PROBLEM TO BE SOLVED: To maintain or increase vessel lumen diameter in a diseased or injured blood vessel of a mammal, i.e. to suppress the restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension.SOLUTION: TGF-beta activators and TGF-beta produc ...